Autopsy report · NCT00994214

Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Preliminary data from this study does not support expected inhibition of GH and IGF-1”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year 4 months before it stopped.
109 participants enrolled.
Results were posted on the registry 5 years after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Ipsen
Sponsor type: Industry
Conditions: Acromegaly
Interventions: BIM 23A760
Participants: 109
Sites: 23
Countries: Belgium, Brazil, Czechia, France, Latvia, Lithuania, Mexico, Netherlands, Poland, Romania, Sweden, Ukraine and more

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.